Sulfobutyl ether-β-cyclodextrin sodium salt (SBE-β-CD) is a novel anionic, highly water-soluble cyclodextrin derivative widely used as a pharmaceutical excipient. It forms non-covalent inclusion complexes with drug molecules, thereby enhancing drug stability, aqueous solubility, safety, and bioavailability. It exhibits low nephrotoxicity, mitigates drug-induced hemolysis, and modulates drug release kinetics. SBE-β-CD demonstrates superior solubilizing capacity over a wide concentration range compared to unmodified β-cyclodextrin, making it particularly effective for formulating poorly soluble drugs. It is also used in vivo as a solubilizing and stabilizing agent, for example, in 20% (w/v) aqueous saline solutions for preclinical and clinical applications.